180 related articles for article (PubMed ID: 32330423)
41. Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential.
Smyth P; Sasiwachirangkul J; Williams R; Scott CJ
Mol Aspects Med; 2022 Dec; 88():101106. PubMed ID: 35868042
[TBL] [Abstract][Full Text] [Related]
42. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.
Han G; Deng Q; Marques-Piubelli ML; Dai E; Dang M; Ma MCJ; Li X; Yang H; Henderson J; Kudryashova O; Meerson M; Isaev S; Kotlov N; Nomie KJ; Bagaev A; Parra ER; Solis Soto LM; Parmar S; Hagemeister FB; Ahmed S; Iyer SP; Samaniego F; Steiner R; Fayad L; Lee H; Fowler NH; Flowers CR; Strati P; Westin JR; Neelapu SS; Nastoupil LJ; Vega F; Wang L; Green MR
Blood Cancer Discov; 2022 Sep; 3(5):428-443. PubMed ID: 35687817
[TBL] [Abstract][Full Text] [Related]
43. Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner.
Lautwein A; Kraus M; Reich M; Burster T; Brandenburg J; Overkleeft HS; Schwarz G; Kammer W; Weber E; Kalbacher H; Nordheim A; Driessen C
J Leukoc Biol; 2004 May; 75(5):844-55. PubMed ID: 14966190
[TBL] [Abstract][Full Text] [Related]
44. Redundancy between Cysteine Cathepsins in Murine Experimental Autoimmune Encephalomyelitis.
Allan ER; Yates RM
PLoS One; 2015; 10(6):e0128945. PubMed ID: 26075905
[TBL] [Abstract][Full Text] [Related]
45. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages.
Beers C; Honey K; Fink S; Forbush K; Rudensky A
J Exp Med; 2003 Jan; 197(2):169-79. PubMed ID: 12538657
[TBL] [Abstract][Full Text] [Related]
46. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs.
Bania J; Gatti E; Lelouard H; David A; Cappello F; Weber E; Camosseto V; Pierre P
Proc Natl Acad Sci U S A; 2003 May; 100(11):6664-9. PubMed ID: 12748383
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
Xie M; Jiang Q; Zhao S; Zhao J; Ye X; Qian W
Int Immunopharmacol; 2020 Aug; 85():106684. PubMed ID: 32540726
[TBL] [Abstract][Full Text] [Related]
48. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism.
Villadangos JA; Riese RJ; Peters C; Chapman HA; Ploegh HL
J Exp Med; 1997 Aug; 186(4):549-60. PubMed ID: 9254653
[TBL] [Abstract][Full Text] [Related]
49. Cathepsins and compartmentalization in antigen presentation.
Riese RJ; Chapman HA
Curr Opin Immunol; 2000 Feb; 12(1):107-13. PubMed ID: 10679409
[TBL] [Abstract][Full Text] [Related]
50. Improvement of cathepsin S detection using a designed FRET peptide based on putative natural substrates.
Oliveira M; Torquato RJ; Alves MF; Juliano MA; Brömme D; Barros NM; Carmona AK
Peptides; 2010 Apr; 31(4):562-7. PubMed ID: 20045715
[TBL] [Abstract][Full Text] [Related]
51. Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.
Chevalier N; Mueller M; Mougiakakos D; Ihorst G; Marks R; Schmitt-Graeff A; Veelken H
Leuk Lymphoma; 2016 Sep; 57(9):2150-60. PubMed ID: 26757600
[TBL] [Abstract][Full Text] [Related]
52. Tissue-Specific Factors Differentially Regulate the Expression of Antigen-Processing Enzymes During Dendritic Cell Ontogeny.
Mahiddine K; Hassel C; Murat C; Girard M; Guerder S
Front Immunol; 2020; 11():453. PubMed ID: 32296417
[TBL] [Abstract][Full Text] [Related]
53. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
Fineschi B; Sakaguchi K; Appella E; Miller J
J Immunol; 1996 Oct; 157(8):3211-5. PubMed ID: 8871612
[TBL] [Abstract][Full Text] [Related]
54. Symbiotic gut commensal bacteria act as host cathepsin S activity regulators.
Steimle A; Gronbach K; Beifuss B; Schäfer A; Harmening R; Bender A; Maerz JK; Lange A; Michaelis L; Maurer A; Menz S; McCoy K; Autenrieth IB; Kalbacher H; Frick JS
J Autoimmun; 2016 Dec; 75():82-95. PubMed ID: 27484364
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor.
Podolin PL; Bolognese BJ; Carpenter DC; Davis TG; Johanson RA; Fox JH; Long E; Dong X; Marquis RW; Locastro SM; Terfloth GJ; Kurali E; Peterson JJ; Smith BR; McQueney MS; Yamashita DS; Capper-Spudich EA
J Immunol; 2008 Jun; 180(12):7989-8003. PubMed ID: 18523262
[TBL] [Abstract][Full Text] [Related]
56. Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain.
Faure-André G; Vargas P; Yuseff MI; Heuzé M; Diaz J; Lankar D; Steri V; Manry J; Hugues S; Vascotto F; Boulanger J; Raposo G; Bono MR; Rosemblatt M; Piel M; Lennon-Duménil AM
Science; 2008 Dec; 322(5908):1705-10. PubMed ID: 19074353
[TBL] [Abstract][Full Text] [Related]
57. Expression of cathepsins B, L, S, and D by gastric epithelial cells implicates them as antigen presenting cells in local immune responses.
Barrera C; Ye G; Espejo R; Gunasena S; Almanza R; Leary J; Crowe S; Ernst P; Reyes VE
Hum Immunol; 2001 Oct; 62(10):1081-91. PubMed ID: 11600214
[TBL] [Abstract][Full Text] [Related]
58. Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue.
Zavasnik-Bergant V; Sekirnik A; Golouh R; Turk V; Kos J
Biol Chem; 2001 May; 382(5):799-804. PubMed ID: 11517933
[TBL] [Abstract][Full Text] [Related]
59. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
[TBL] [Abstract][Full Text] [Related]
60. The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation.
Nakagawa TY; Rudensky AY
Immunol Rev; 1999 Dec; 172():121-9. PubMed ID: 10631942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
